168 related articles for article (PubMed ID: 12065709)
1. Pharmacology of N-(3,5-dichloro-1-oxido-4-pyridinyl)-8-methoxy-2-(trifluoromethyl)-5-quinoline carboxamide (SCH 351591), a novel, orally active phosphodiesterase 4 inhibitor.
Billah MM; Cooper N; Minnicozzi M; Warneck J; Wang P; Hey JA; Kreutner W; Rizzo CA; Smith SR; Young S; Chapman RW; Dyke H; Shih NY; Piwinski JJ; Cuss FM; Montana J; Ganguly AK; Egan RW
J Pharmacol Exp Ther; 2002 Jul; 302(1):127-37. PubMed ID: 12065709
[TBL] [Abstract][Full Text] [Related]
2. In vivo efficacy in airway disease models of roflumilast, a novel orally active PDE4 inhibitor.
Bundschuh DS; Eltze M; Barsig J; Wollin L; Hatzelmann A; Beume R
J Pharmacol Exp Ther; 2001 Apr; 297(1):280-90. PubMed ID: 11259555
[TBL] [Abstract][Full Text] [Related]
3. Antiasthmatic activity of the second-generation phosphodiesterase 4 (PDE4) inhibitor SB 207499 (Ariflo) in the guinea pig.
Underwood DC; Bochnowicz S; Osborn RR; Kotzer CJ; Luttmann MA; Hay DW; Gorycki PD; Christensen SB; Torphy TJ
J Pharmacol Exp Ther; 1998 Dec; 287(3):988-95. PubMed ID: 9864284
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and profile of SCH351591, a novel PDE4 inhibitor.
Billah M; Cooper N; Cuss F; Davenport RJ; Dyke HJ; Egan R; Ganguly A; Gowers L; Hannah DR; Haughan AF; Kendall HJ; Lowe C; Minnicozzi M; Montana JG; Naylor R; Oxford J; Peake JC; Piwinski JJ; Runcie KA; Sabin V; Sharpe A; Shih NY; Warneck JB
Bioorg Med Chem Lett; 2002 Jun; 12(12):1621-3. PubMed ID: 12039576
[TBL] [Abstract][Full Text] [Related]
5. Cilomilast: a second generation phosphodiesterase 4 inhibitor for asthma and chronic obstructive pulmonary disease.
Giembycz MA
Expert Opin Investig Drugs; 2001 Jul; 10(7):1361-79. PubMed ID: 11772257
[TBL] [Abstract][Full Text] [Related]
6. Effects of ciclamilast, a new PDE 4 PDE4 inhibitor, on airway hyperresponsiveness, PDE4D expression and airway inflammation in a murine model of asthma.
Deng YM; Xie QM; Tang HF; Sun JG; Deng JF; Chen JQ; Yang SY
Eur J Pharmacol; 2006 Oct; 547(1-3):125-35. PubMed ID: 16956605
[TBL] [Abstract][Full Text] [Related]
7. Anti-inflammatory and bronchodilator properties of RP 73401, a novel and selective phosphodiesterase type IV inhibitor.
Raeburn D; Underwood SL; Lewis SA; Woodman VR; Battram CH; Tomkinson A; Sharma S; Jordan R; Souness JE; Webber SE
Br J Pharmacol; 1994 Dec; 113(4):1423-31. PubMed ID: 7889300
[TBL] [Abstract][Full Text] [Related]
8. Pharmacology of a new cyclic nucleotide phosphodiesterase type 4 inhibitor, V11294.
Gale DD; Hofer P; Spina D; Seeds EA; Banner KH; Harrison S; Douglas G; Matsumoto T; Page CP; Wong RH; Jordan S; Smith F; Banik N; Halushka PV; Cavalla D; Rotshteyn Y; Kyle DJ; Burch RM; Chasin M
Pulm Pharmacol Ther; 2003; 16(2):97-104. PubMed ID: 12670778
[TBL] [Abstract][Full Text] [Related]
9. L-454,560, a potent and selective PDE4 inhibitor with in vivo efficacy in animal models of asthma and cognition.
Huang Z; Dias R; Jones T; Liu S; Styhler A; Claveau D; Otu F; Ng K; Laliberte F; Zhang L; Goetghebeur P; Abraham WM; Macdonald D; Dubé D; Gallant M; Lacombe P; Girard Y; Young RN; Turner MJ; Nicholson DW; Mancini JA
Biochem Pharmacol; 2007 Jun; 73(12):1971-81. PubMed ID: 17428447
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of airway hyperresponsiveness and pulmonary inflammation by roflumilast and other PDE4 inhibitors.
Wollin L; Bundschuh DS; Wohlsen A; Marx D; Beume R
Pulm Pharmacol Ther; 2006; 19(5):343-52. PubMed ID: 16257550
[TBL] [Abstract][Full Text] [Related]
11. In vivo efficacy in airway disease models of N-(3,5-dichloropyrid-4-yl)-[1-(4-fluorobenzyl)-5-hydroxy-indole-3-yl]-glyoxylic acid amide (AWD 12-281), a selective phosphodiesterase 4 inhibitor for inhaled administration.
Kuss H; Hoefgen N; Johanssen S; Kronbach T; Rundfeldt C
J Pharmacol Exp Ther; 2003 Oct; 307(1):373-85. PubMed ID: 12944497
[TBL] [Abstract][Full Text] [Related]
12. CDP840. A prototype of a novel class of orally active anti-inflammatory phosphodiesterase 4 inhibitors.
Alexander RP; Warrellow GJ; Eaton MA; Boyd EC; Head JC; Porter JR; Brown JA; Reuberson JT; Hutchinson B; Turner P; Boyce B; Barnes D; Mason B; Cannell A; Taylor RJ; Zomaya A; Millican A; Leonard J; Morphy R; Wales M; Perry M; Allen RA; Gozzard N; Hughes B; Higgs G
Bioorg Med Chem Lett; 2002 Jun; 12(11):1451-6. PubMed ID: 12031318
[TBL] [Abstract][Full Text] [Related]
13. Synthesis, structure-activity relationships, and pharmacological profile of 9-amino-4-oxo-1-phenyl-3,4,6,7-tetrahydro[1,4]diazepino[6, 7,1-hi]indoles: discovery of potent, selective phosphodiesterase type 4 inhibitors.
Burnouf C; Auclair E; Avenel N; Bertin B; Bigot C; Calvet A; Chan K; Durand C; Fasquelle V; Féru F; Gilbertsen R; Jacobelli H; Kebsi A; Lallier E; Maignel J; Martin B; Milano S; Ouagued M; Pascal Y; Pruniaux MP; Puaud J; Rocher MN; Terrasse C; Wrigglesworth R; Doherty AM
J Med Chem; 2000 Dec; 43(25):4850-67. PubMed ID: 11123995
[TBL] [Abstract][Full Text] [Related]
14. Anti-inflammatory potential of the selective phosphodiesterase 4 inhibitor N-(3,5-dichloro-pyrid-4-yl)-[1-(4-fluorobenzyl)-5-hydroxy-indole-3-yl]-glyoxylic acid amide (AWD 12-281), in human cell preparations.
Draheim R; Egerland U; Rundfeldt C
J Pharmacol Exp Ther; 2004 Feb; 308(2):555-63. PubMed ID: 14610230
[TBL] [Abstract][Full Text] [Related]
15. The inhibition of antigen-induced eosinophilia and bronchoconstriction by CDP840, a novel stereo-selective inhibitor of phosphodiesterase type 4.
Hughes B; Howat D; Lisle H; Holbrook M; James T; Gozzard N; Blease K; Hughes P; Kingaby R; Warrellow G; Alexander R; Head J; Boyd E; Eaton M; Perry M; Wales M; Smith B; Owens R; Catterall C; Lumb S; Russell A; Allen R; Merriman M; Bloxham D; Higgs G
Br J Pharmacol; 1996 Jul; 118(5):1183-91. PubMed ID: 8818342
[TBL] [Abstract][Full Text] [Related]
16. Anti-inflammatory and immunomodulatory potential of the novel PDE4 inhibitor roflumilast in vitro.
Hatzelmann A; Schudt C
J Pharmacol Exp Ther; 2001 Apr; 297(1):267-79. PubMed ID: 11259554
[TBL] [Abstract][Full Text] [Related]
17. 7-Methoxyfuro[2,3-c]pyridine-4-carboxamides as PDE4 inhibitors: a potential treatment for asthma.
Buckley GM; Cooper N; Davenport RJ; Dyke HJ; Galleway FP; Gowers L; Haughan AF; Kendall HJ; Lowe C; Montana JG; Oxford J; Peake JC; Picken CL; Richard MD; Sabin V; Sharpe A; Warneck JB
Bioorg Med Chem Lett; 2002 Feb; 12(3):509-12. PubMed ID: 11814830
[TBL] [Abstract][Full Text] [Related]
18. Effects of a selective PDE4 inhibitor, D-22888, on human airways and eosinophils in vitro and late phase allergic pulmonary eosinophilia in guinea pigs.
Dent G; Poppe H; Egerland J; Marx D; Szelenyi I; Branscheid D; Magnussen H; Rabe KF
Pulm Pharmacol Ther; 1998 Feb; 11(1):13-21. PubMed ID: 9802959
[TBL] [Abstract][Full Text] [Related]
19. Phosphodiesterase inhibitors reduce bronchial hyperreactivity and airway inflammation in unrestrained guinea pigs.
Santing RE; Olymulder CG; Van der Molen K; Meurs H; Zaagsma J
Eur J Pharmacol; 1995 Feb; 275(1):75-82. PubMed ID: 7774665
[TBL] [Abstract][Full Text] [Related]
20. SB 207499 (Ariflo), a second generation phosphodiesterase 4 inhibitor, reduces tumor necrosis factor alpha and interleukin-4 production in vivo.
Griswold DE; Webb EF; Badger AM; Gorycki PD; Levandoski PA; Barnette MA; Grous M; Christensen S; Torphy TJ
J Pharmacol Exp Ther; 1998 Nov; 287(2):705-11. PubMed ID: 9808700
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
